Immunarray

ImmunarrayImmunarray
Immunarray

Immunarray

ImmunArray develops and markets novel multi-analyte blood-based tests for complex immune-mediated diseases using its iCHIP microarray platform.

Website
2006Inactive
Rate
Advertise here

About

ImmunArray is a biotechnology company focused on the development and commercialization of advanced diagnostic tools for autoimmune and neurological disorders. Their proprietary iCHIP microarray platform enables the detection of multiple biomarkers from a single blood sample, aiming to improve diagnosis and management of complex immune-mediated diseases.

Technology stack

detected 2026-06-26
EmailGoogle Workspace
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Immunarray do?

ImmunArray is a biotechnology company focused on the development and commercialization of advanced diagnostic tools for autoimmune and neurological disorders. Their proprietary iCHIP microarray platform enables the detection of multiple biomarkers from a single blood sample, aiming to improve diagnosis and management of complex immune-mediated diseases.

How much funding has Immunarray raised?

Immunarray has raised a total of $10M in funding. The most recent round on record is Series A.

Where is Immunarray headquartered?

Immunarray is headquartered in Richmond, United States.

When was Immunarray founded?

Immunarray was founded in 2006.

What industry does Immunarray operate in?

Immunarray operates in Healthcare, Blood, Diagnostics, Immunology, Biomarkers, Biotech.

What is Immunarray's current status?

Immunarray's current operating status is: Inactive.

What is Immunarray's revenue?

StartupHub estimates Immunarray's annual revenue at $2.7M (range $1.5M to $4.7M, 30% confidence), based on comparable companies in the sector.

What is Immunarray's valuation?

StartupHub estimates Immunarray's effective valuation at $37.4M (range $25.0M to $60.0M, 10% confidence), based on comparable companies in the sector.